interleukin 1 and 2 production in homosexual men: a controlled trial of therafectin (sm-1213), a possible immunomodulator.

NLM AIDSLINE Interleukin 1 and 2 production in homosexual men: a controlled trial of therafectin (SM-1213), a possible immunomodulator. Goldsmith JM; Huprikar J; Wu SJ; Phair JP
September 30, 1986

J Immunopharmacol. 1986;8(1):1-14. Unique Identifier : AIDSLINE Patients with the acquired immunodeficiency syndrome (AIDS) are susceptible to a variety of opportunistic pathogens which require intact cellular immunity for control and eradication. We evaluated interleukin 1 and 2 production in 12 homosexual men without AIDS but with evidence of altered cell-mediated immunity and serologic evidence of infection with human T-cell lymphotrophic virus type III (HTLV-III), the etiologic agent of AIDS and found production of both factors diminished compared to heterosexual controls. Therafectin (SM-1213) is a new agent which selectively activates macrophages and stimulated interleukin 1 production in vitro. Therafectin was administered to these same 12 patients in a double-blind, placebo controlled trial. We failed to find any significant changes in their immunologic status including interleukin 1 or 2 production. Acquired Immunodeficiency Syndrome/IMMUNOLOGY Adjuvants, Immunologic/THERAPEUTIC USE Clinical Trials Comparative Study Glucosamine/ANALOGS & DERIVATIVES/IMMUNOLOGY/THERAPEUTIC USE Homosexuality Human Immunity, Cellular/DRUG EFFECTS Interleukin-1/METABOLISM Interleukin-2/METABOLISM Male T-Lymphocytes, Cytotoxic/DRUG EFFECTS/IMMUNOLOGY/METABOLISM T-Lymphocytes, Helper-Inducer/DRUG EFFECTS/IMMUNOLOGY/METABOLISM CLINICAL TRIAL JOURNAL ARTICLE

Most Read: Latest Added Related Topics White House LGBT Conference on HIV/AIDS UNITED STATES: White House in Atlanta: LGBT AIDS Conference No more single-theme conferences: global HIV prevention conference planned FHI 360 Senior Scientist Lut Van Damme Receives International Microbicide Conference Lifetime Achievement Award Equatorial Guinea Ministry of Health and Social Welfare and UNICEF Refute Erroneous AIDS Prevalence Figures Photographs from A Day with HIV Now Online Bulgaria urges Libya to investigate AIDS nurses case Engineers enter fight against AIDS in Africa Gilead’s Complera® Non-Inferior to Atripla® Among Treatment-Naive HIV Patients UN chief Ban calls world leaders to end Aids by 2020 CANADA: Health Officials in St. John's N.L., Inform 50 People of Tuberculosis Risk OHIO: Cleveland LGBT Community Center Offers Free Support Groups and HIV, STD Testing: The Frugal Patient CALIFORNIA: Local Church Sends HIV/AIDS Care Packs to Swaziland NEVADA: Clinics Offer Low-Cost Care for those Lacking Insurance CONNECTICUT: At Hartford Public High School, A Day Reserved for 'Healthy Relationships' ITALY: HIV Is No Barrier to Successful Liver Transplant for Cancer Treatment KENYA: Kenya Launches Universal HPV Vaccine Access to Youths UNITED STATES: Navajo Confront an Increase in New H.I.V. Infections Uganda: HIV Vaccine Trials to Start in July Uganda: Remembering Those Killed By HIV/AIDS (International AIDS Candlelight Memorial) Uganda: HIV Vaccine Trials to Start in July Initiation rules help to keep young men safe and healthy India Widens Price Control Over Medicines Experimental Gilead drug effective in early-stage leukemia trial NORTH CAROLINA: Possible Exposure to Hepatitis A THE NETHERLANDS: High Prevalence of Oral HPV Infection in Dutch Gay Men Schistosomiasis control a route to cutting HIV in Africa ITALY: HIV Meds Protect Against Doubled Cancer Risk in Positive Men Jury to be seated, Vegas hep C trial due to start $5M bail for HIV positive man charged with sexual assault
Information in this article was accurate in September 30, 1986. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.